65,437 trials
Multiple Myeloma
Primary: Number of Participants With Adverse Events (AEs) — 10; 12; 34; 9 Participants
Neovascular Age-Related Macular Degeneration
Primary: Mean Change in Central Retinal Subfield Thickness as Measured by Optical Coherence Tomography (OCT) at Week 24 From Baseline — -98; -66; -180.8 Microns
Osteoarthritis
Primary: Number of Participants With Venous Thromboembolism — 0; 3 Participants
Fallopian Tube Clear Cell Adenocarcinoma · Fallopian Tube Endometrioid Adenocarcinoma · Fallopian Tube Mucinous Adenocarcinoma
Primary: Incidence of Adverse Events Assessed by Common Terminology Criteria for Adverse Events — 1; 9; 20; 9 Participants
Alzheimer Disease
Primary: Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 Item (ADAS-Cog11) Total Score After 12 Weeks of Treatment — 0.026; 0.175; 0.699…
Sleep Disorders
Primary: Total Sleep Time — 6.62; 6.55 hours — p=0.60
Trauma-related Wound · Surgical Wound, Recent
Primary: Wound Closure — 22 Participants
Uncontrolled Hypertension · Atrial Fibrillation
Primary: Anti-arrhythmic Drug (AAD)-Free Single-procedure Freedom From Atrial Fibrillation Recurrence — 6; 2 recurrences
Post-operative Pain
Primary: Opioid Consumption at 24 Hours Post-op — 22.9; 58.1 milligrams of oral morphine equivalents
Arthritis, Psoriatic
Primary: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 — 32.9; 64.1; 63.7 percentage of participants — p=< 0.001
Amygdala Activation
Primary: Acute Effect of a rTMS Session on Brain Activation as Measured by the Cerebral Blood Flow (Blood Oxygenation Level Dependent Signal) — 0.67; -0.48 z score in the…
Cardiomyopathy Due to Anthracyclines
Primary: Proportion of Major Adverse Cardiac Events (MACE) — 3; 6 events
Alzheimer Disease · Mild to Moderate Alzheimer Disease
Primary: Frequency of Treatment-emergent Adverse Events (Safety) — 18; 20 Participants
Open Angle Glaucoma · Ocular Hypertension · Glaucoma, Open Angle, Pseudo-exfoliative
Primary: Intraocular Pressure (IOP) Measured by Tonometry in Millimeters of Mercury at Three Months of Follow-up — 20.7; 19.1 mm Hg
COVID-19
Primary: Rate of Clinical Status Improvement — 27; 15 Participants — p=0.0372